April 14, 2022
April 4, 2022 – Several years following FDA approval, Ibsrela® (tenapanor) oral tablets are now available to treat irritable bowel syndrome with constipation (IBS-C) in adults
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Pharmacy Benefits Management
April 14, 2022
March 29, 2022 – Teva Pharmaceuticals has recalled lot 31329657B of IDArubicin Hydrochloride Injection USP 5mg/5mL vials. An internal inspection found one vial contained silica
April 14, 2022
April 14, 2022 – The U.S. FDA has approved Imcivree® (setmelanotide) for treatment of obesity and control of hunger in patients who are at least six years old and have Bardet-Biedl
April 13, 2022
April 13, 2022 – Amneal has received FDA approval for Alymsys® (bevacizumab-maly) intravenous injection, a biosimilar to Genentech’s Avastin®
April 11, 2022
April 11, 2022 – Xigduo® XR (dapagliflozin/metformin) has received a new indication for one of its active pharmaceutical ingredients (APIs), dapagliflozin, to reduce the risk of
April 8, 2022
April 8, 2022 – ArmonAir® Digihaler® (fluticasone propionate) has received an expanded indication to
provide maintenance treatment (as prophylactic therapy) for asthma in patients
April 6, 2022
April 6, 2022 – Novartis has obtained FDA approval for Vijoice® (alpelisib) to treat severe manifestations
of PIK3CA-related overgrowth spectrum (PROS) in patients at least two years of age
April 6, 2022
April 6, 2022 – IgalmiTM (dexmedetomidine) sublingual film, made by BioXcel Therapeutics, has received FDA approval to treat agitation associated with schizophrenia